Fiscal Nepal
First Business News Portal in English from Nepal
KATHMANDU: Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The International Vaccine Institute (IVI), an international organization dedicated to the discovery, development and delivery of safe, effective and affordable vaccines, will...